Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.30USD
−46.05 MUSD
27.46 MUSD
43.10 M
About Zevra Therapeutics, Inc.
Sector
CEO
Neil F. McFarlane
Headquarters
Celebration
Website
Employees (FY)
69
Founded
2006
FIGI
BBG0026ZG1F5
Zevra Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ZVRA is 5.16 USD — it has increased by 7.28% in the past 24 hours. Watch Zevra Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Zevra Therapeutics, Inc. stocks are traded under the ticker ZVRA.
Zevra Therapeutics, Inc. is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
ZVRA stock is 7.60% volatile and has beta coefficient of 1.33. Track Zevra Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Zevra Therapeutics, Inc. there?
ZVRA earnings for the last quarter are −0.51 USD per share, whereas the estimation was −0.27 USD resulting in a −90.06% surprise. The estimated earnings for the next quarter are −0.47 USD per share. See more details about Zevra Therapeutics, Inc. earnings.
Zevra Therapeutics, Inc. revenue for the last quarter amounts to 13.20 M USD despite the estimated figure of 11.73 M USD. In the next quarter revenue is expected to reach 3.76 M USD.
Yes, you can track Zevra Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
ZVRA stock has risen by 13.16% compared to the previous week, the month change is a 4.45% rise, over the last year Zevra Therapeutics, Inc. has showed a 4.67% increase.
ZVRA net income for the last quarter is −15.15 M USD, while the quarter before that showed −14.05 M USD of net income which accounts for −7.89% change. Track more Zevra Therapeutics, Inc. financial stats to get the full picture.
Today Zevra Therapeutics, Inc. has the market capitalization of 208.88 M, it has increased by 5.71% over the last week.
No, ZVRA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ZVRA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Zevra Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
ZVRA reached its all-time high on Aug 14, 2015 with the price of 418.40 USD, and its all-time low was 1.94 USD and was reached on May 21, 2020. View more price dynamics on ZVRA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
As of May 6, 2024, the company has 69.00 employees. See our rating of the largest employees — is Zevra Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Zevra Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Zevra Therapeutics, Inc. stock shows the sell signal. See more of Zevra Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Zevra Therapeutics, Inc. future price: according to them, ZVRA price has a max estimate of 24.00 USD and a min estimate of 14.00 USD. Watch ZVRA chart and read a more detailed Zevra Therapeutics, Inc. stock forecast: see what analysts think of Zevra Therapeutics, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Zevra Therapeutics, Inc. EBITDA is −48.60 M USD, and current EBITDA margin is −176.97%. See more stats in Zevra Therapeutics, Inc. financial statements.